These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6215817)

  • 1. Treatment of myoclonic syndromes with paroxetine alone or combined with 5-HTP.
    Magnussen I; Mondrup K; Engbaek F; Lademann A; Olivarius BD
    Acta Neurol Scand; 1982 Aug; 66(2):276-82. PubMed ID: 6215817
    [No Abstract]   [Full Text] [Related]  

  • 2. Serotonin and myoclonic seizures.
    Munsat TL
    N Engl J Med; 1977 Jan; 296(2):101-2. PubMed ID: 299730
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of intravenous L-5-HTP in the myoclonic encephalopathy of infants.
    Gobbi G; Melideo G; Giovanardi Rossi P
    Neuropediatrics; 1986 May; 17(2):63-5. PubMed ID: 3014368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
    Van Woert MH; Rosenbaum D; Howieson J; Bowers MB
    N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent.
    Growdon JH; Young RR; Shahani BT
    Neurology; 1976 Dec; 26(12):1135-40. PubMed ID: 1086988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimyoclonic properties of S2 serotonin receptor antagonists in the rat.
    Pranzatelli MR; Snodgrass SR
    Neuropharmacology; 1986 Jan; 25(1):5-12. PubMed ID: 2936977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
    Van Woert MH; Sethy VH
    Neurology; 1975 Feb; 25(2):135-40. PubMed ID: 1078720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin and myoclonus.
    Van Woert MH; Jutkowitz R; Rosenbaum D; Bowers MB
    Monogr Neural Sci; 1976; 3():71-80. PubMed ID: 790170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, biochemical, and pharmacological observation in a patient with postasphyxic myoclonus: association to serotonin hyperactivity.
    Giménez-Roldán S; Mateo D; Muradas V; De Yebenes JG
    Clin Neuropharmacol; 1988 Apr; 11(2):151-60. PubMed ID: 2454156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam.
    Chadwick D; Hallett M; Harris R; Jenner P; Reynolds EH; Marsden CD
    Brain; 1977 Sep; 100(3):455-87. PubMed ID: 412560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of L-5HTP and drugs acting on serotonin metabolism in various myoclonic syndromes.
    Avanzini G; Bossi L; Caraceni T; Consolazione A; Franceschetti S; Negri S; Parati E
    Monogr Neural Sci; 1980; 5():142-52. PubMed ID: 6976509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa.
    Thal L; Sharpless N; Wolfson L; Engel J; Katzman R
    Trans Am Neurol Assoc; 1976; 101():48-52. PubMed ID: 1088459
    [No Abstract]   [Full Text] [Related]  

  • 13. Functional independence in post-anoxic myoclonus: contribution of L-5-HTP sodium valproate and clonazepam.
    Carroll WM; Walsh PJ
    Br Med J; 1978 Dec; 2(6152):1612. PubMed ID: 365292
    [No Abstract]   [Full Text] [Related]  

  • 14. L-5-hydroxytryptophan therapy in myoclonus.
    Van Woert MH; Rosenbaum D
    Adv Neurol; 1979; 26():107-15. PubMed ID: 316273
    [No Abstract]   [Full Text] [Related]  

  • 15. Spinal myoclonus: successful treatment with the combination of sodium valproate and L-5-hydroxytryptophan.
    Jiménez-Jiménez FJ; Roldan A; Zancada F; Molina-Arjona JA; Fernandez-Ballesteros A; Santos J
    Clin Neuropharmacol; 1991 Apr; 14(2):186-90. PubMed ID: 2015615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postanoxic myoclonus. Treatment of a case with 5-hydroxytryptophane and a decarboxylase inhibitor.
    Beretta E; Regli F; de Crousaz G; Steck AJ
    J Neurol; 1981; 225(1):57-62. PubMed ID: 6164757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Letter: Combination of a dopa decarboxylase inhibitor with 5-hydroxytryptophan therapy].
    Lhermitte F; Degos CF; Marteau R
    Nouv Presse Med; 1975 Jan; 4(1):31. PubMed ID: 1079935
    [No Abstract]   [Full Text] [Related]  

  • 18. Manipulation of brain serotonin in the treatment of myoclonus.
    Chadwick D; Jenner P; Harris R; Reynolds EH; Marsden CD
    Lancet; 1975 Sep; 2(7932):434-5. PubMed ID: 51240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Utilization of levo-5-hydroxytryptophan in post-anoxic myoclonus].
    Rascol A; Guiraud-Chaumeil B; Laboucarie J; Montastruc JL; El-Hage W
    Therapie; 1978; 33(5):623-8. PubMed ID: 311085
    [No Abstract]   [Full Text] [Related]  

  • 20. Myoclonus and L-5-hydroxytryptophan (L-5HTP).
    Van Woert MH
    Prog Clin Biol Res; 1983; 127():43-52. PubMed ID: 6351100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.